Objective Race and household income impact outcomes in patients with rheumatic conditions; however, their role in pediatric antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) remains poorly understood. We aimed to evaluate whether race and ethnicity and household income are associated with severe AAV disease and renal outcomes among
Roberto Alejandro Valdovinos +2 more
wiley +1 more source
Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database. [PDF]
Yang Y +6 more
europepmc +1 more source
Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa +3 more
wiley +1 more source
A descriptive, retrospective analysis of the quality of spontaneous adverse event reporting to the Côte d'Ivoire Pharmaceutical and Regulatory Authority and its impact on the causality assessment. [PDF]
Kamagaté M +7 more
europepmc +1 more source
Adverse Event Profiles of Acetaminophen and Ibuprofen in Infants: A Food and Drug Administration Adverse Event Reporting System Database Retrospective Cohort Study. [PDF]
Bao Y, Lv HF, Li X, Chen BH.
europepmc +1 more source
The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort
Objective Cardiac involvement significantly impacts prognosis in systemic sclerosis (SSc), highlighting the need for early risk stratification. Gastrointestinal (GI) symptoms are common and often manifest early. Emerging data suggest a link between GI and cardiac manifestations, possibly through shared mechanisms like dysautonomia.
Francesca R. Di Ciommo +9 more
wiley +1 more source
Global pharmacovigilance reporting: comparative analysis of adverse event obligations across five major regulatory authorities. [PDF]
Bernaus CG, Bournissen ML.
europepmc +1 more source
Real-world pharmacovigilance analysis of pralatrexate using the FDA adverse event reporting system database. [PDF]
Yang W +6 more
europepmc +1 more source
"It isn't an adverse event": junior nurses' perceptions of adverse events and attribution of causes. [PDF]
Qi L, Xu J, Mao A.
europepmc +1 more source

